The FDA has approved a higher 7.2 mg dose of Novo Nordisk’s Wegovy (Wegovy HD) for chronic weight management in adults with ...
In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity. In the phase 3b STEP ...
Anti-obesity medications used with lifestyle intervention produce greater and more sustained weight loss than does lifestyle intervention alone. However, until 2021, FDA-approved medications for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results